{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:40:19Z","timestamp":1789094419568,"version":"build-2803163510"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Invasive aspergillosis remains a major cause of death among the immunocompromised population and those receiving long-term immunosuppressive therapy. In light of increased azole resistance, variable outcomes with existing echinocandin monotherapy and combination therapy, and persistent high mortality rates, new antifungal agents for the treatment of invasive aspergillosis are clearly needed. SCY-078 is the first-in-class triterpenoid antifungal, a novel class of glucan synthase inhibitors with broad\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    activity against a broad spectrum of\n                    <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">Aspergillus<\/jats:named-content>\n                    species.\n                    <jats:italic>In vitro<\/jats:italic>\n                    testing of clinical strains of\n                    <jats:named-content content-type=\"genus-species\">Aspergillus fumigatus<\/jats:named-content>\n                    and non-\n                    <jats:named-content content-type=\"genus-species\">fumigatus Aspergillus<\/jats:named-content>\n                    strains showed that SCY-078 had potent fungistatic activity (minimum effective concentration for 90% of strains tested = 0.125 \u03bcg\/ml) compared with the activities of amphotericin B (MIC\n                    <jats:sub>90<\/jats:sub>\n                    = 8 \u03bcg\/ml) and voriconazole (MIC\n                    <jats:sub>90<\/jats:sub>\n                    = 2 \u03bcg\/ml). Testing of SCY-078 in combination with isavuconazole or voriconazole demonstrated synergistic activity against the majority of the azole-susceptible strains tested, and SCY-078 in combination with amphotericin B was synergistic against the azole-susceptible strains, as well as one known resistant\n                    <jats:italic>cyp51A<\/jats:italic>\n                    mutant. SCY-078 may be an important additional antifungal for first-line or salvage monotherapy or combination treatment of invasive aspergillosis.\n                  <\/jats:p>","DOI":"10.1128\/aac.00244-18","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T06:11:39Z","timestamp":1522649499000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":77,"title":["Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis"],"prefix":"10.1128","volume":"62","author":[{"given":"M.","family":"Ghannoum","sequence":"first","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Long","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Larkin","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Isham","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sherif","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barat","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2017.04.012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2011.1.3.130"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx030"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx032"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990332"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2508"},{"key":"e_1_3_2_9_2","volume-title":"SWAB guidelines for the management of invasive fungal infections","author":"Kullberg BJ","year":"2017","unstructured":"Kullberg BJ, Blijlevens NMA, Janssen JWM, Meis JFG, Verweij PE, Oude Lashof AML, van de Veerdonk FJ, Rijnders BJ, Bruggemann RJM, vd Werf TS, Reijers MHE, van Zanten ARH, de Lange DW, Wolfs TFW, Warris A. 2017. SWAB guidelines for the management of invasive fungal infections. SWAB Secretariat, Bergen, The Netherlands."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-017-0162-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12161"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.08.012"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.07.007"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01588-12"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00161-17"},{"key":"e_1_3_2_16_2","volume-title":"Abstr ECCMID 2018","author":"Cushion M","year":"2018","unstructured":"Cushion M, Ashbaugh A, Borroto-Esoda K, Barat S, Angulo D. 2018. SCY-078 demonstrates antifungal activity against Pneumocystis in a prophylactic murine model of Pneumocystis pneumonia, abstr 969. Abstr ECCMID 2018, Madrid, Spain."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02145-13"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.1.163-194.2005"},{"key":"e_1_3_2_19_2","first-page":"242","article-title":"Voriconazole\u2014better chances for patients with invasive mycoses","volume":"7","author":"Ghannoum MA","year":"2002","unstructured":"Ghannoum MA, Kuhn DM. 2002. Voriconazole\u2014better chances for patients with invasive mycoses. Eur J Med Res 7:242\u2013256.","journal-title":"Eur J Med Res"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1773-1780.2002"},{"key":"e_1_3_2_21_2","volume-title":"CLSI document M38-A2","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. CLSI, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0b013e318059b94b"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00244-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00244-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:17:16Z","timestamp":1645460236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00244-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1128\/AAC.00244-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00244-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"2018-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00244-18"}}